GlassScriptPhysician profile
Roderick J Tompkins
NPI 1306892559
$2,323.85
in general payments reported to CMS, 2019-2025
22 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $198 · 2021: $114 · 2022: $356 · 2023: $294 · 2024: $483 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $945.60 | 2019-2025 | Echelon; Endopath, Harmonic, Enseal |
| Abbvie INC. | $374.44 | 2023-2025 | Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.29 | 2022-2025 | Xifaxan, Trulance |
| Davol INC. | $175.50 | 2019-2020 | |
| Evoke Pharma, INC. | $66.88 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.22 | 2023-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $49.52 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $47.97 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $45.75 | 2022-2023 | Rebyota |
| Qol Medical, LLC | $37.34 | 2025 | Sucraid |
| Aimmune Therapeutics, INC. | $35.99 | 2024 | |
| Mid-Atlantic Surgical Systems, LLC | $26.68 | 2020 | |
| Heron Therapeutics, INC. | $24.27 | 2024 | Zynrelef |
| Smith+Nephew, INC. | $23.07 | 2019 | |
| Conmed Corporation | $20.22 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $19.09 | 2025 | Vegzelma |
| Janssen Biotech, INC. | $17.42 | 2025 | Tremfya |
| Novo Nordisk INC | $17.42 | 2024 | Wegovy |
| Lilly USA, LLC | $16.31 | 2025 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $15.89 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $15.23 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roderick Tompkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.